Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Net Margin (2021 - 2025)

Krystal Biotech's Net Margin history spans 4 years, with the latest figure at 47.99% for Q4 2025.

  • For Q4 2025, Net Margin fell 192.0% year-over-year to 47.99%; the TTM value through Dec 2025 reached 52.64%, up 2195.0%, while the annual FY2025 figure was 52.64%, 2195.0% up from the prior year.
  • Net Margin for Q4 2025 was 47.99% at Krystal Biotech, down from 81.16% in the prior quarter.
  • Across five years, Net Margin topped out at 1059.79% in Q1 2021 and bottomed at 2.06% in Q1 2024.
  • The 4-year median for Net Margin is 40.51% (2025), against an average of 212.75%.
  • The largest annual shift saw Net Margin crashed -91133bps in 2024 before it soared 4874bps in 2025.
  • A 4-year view of Net Margin shows it stood at 1059.79% in 2021, then crashed by -98bps to 20.63% in 2023, then skyrocketed by 142bps to 49.91% in 2024, then dropped by -4bps to 47.99% in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Net Margin are 47.99% (Q4 2025), 81.16% (Q3 2025), and 39.93% (Q2 2025).